Fabrazyme® (agalsidase beta) safety profile
Find out more about the safety and tolerability profile for Fabrazyme®.
Learn more
This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.
Find out more about the safety and tolerability profile for Fabrazyme®.
Explore the results and evidence supporting Fabrazyme® and how it was studied through several clinical trials.
MAT-XU-2305073 (v1.0) Date of preparation: November 2023